institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

OS Therapies announces favorable FDA feedback on clinical strategy for osteosarcoma drug

Summary by Drug Discovery and Development
OS Therapies announced it has received positive written feedback from the U.S. Food and Drug Administration (FDA) following a mid-June Type D meeting. The development supports its plan to use an external control arm to support a Biologics Licensing Application (BLA) for its lead candidate, OST-HER2, a Listeria monocytogenes-based immuno-oncology asset originally developed by Advaxis… The post OS Therapies announces favorable FDA feedback on exte…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Drug Discovery and Development broke the news in on Thursday, June 26, 2025.
Sources are mostly out of (0)